Literature DB >> 19839716

Targeting miR-205 in breast cancer.

Hailong Wu1, Yin-Yuan Mo.   

Abstract

As small non-coding regulatory RNAs, microRNAs are capable of silencing gene expression by translational repression or mRNA degradation. Accumulating evidence indicates that deregulation of microRNAs is often associated with human malignancies and suggests a causal role of microRNAs in neoplasia, presumably because microRNAs can function as oncogenes or tumor suppressors. Among them, miR-205 is significantly underexpressed in breast tumors compared with matched normal breast tissue although miR-205 has been shown to be upregulated in some other type of tumors. Furthermore, breast cancer cell lines, including MCF-7 and MDA-MB-231, express a lower level of miR-205 than the non-malignant MCF-10A cells. Ectopic expression of miR-205 significantly inhibits cell proliferation and anchorage-independent growth as well as cell invasion. These findings establish the tumor suppressive role of miR-205, which is probably through direct targeting of oncogenes such as ErbB3 and Zeb1. Therefore, miR-205 may serve as a unique therapeutic target for breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19839716     DOI: 10.1517/14728220903338777

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  33 in total

1.  Reduction of dietary glycaemic load modifies the expression of microRNA potentially associated with energy balance and cancer pathways in pre-menopausal women.

Authors:  Susan E McCann; Song Liu; Dan Wang; Jie Shen; Qiang Hu; Chi-Chen Hong; Vicky A Newman; Hua Zhao
Journal:  Br J Nutr       Date:  2012-05-30       Impact factor: 3.718

2.  MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.

Authors:  Lei Huo; Yan Wang; Yun Gong; Savitri Krishnamurthy; Jing Wang; Lixia Diao; Chang-Gong Liu; Xiuping Liu; Feng Lin; William F Symmans; Wei Wei; Xinna Zhang; Li Sun; Ricardo H Alvarez; Naoto T Ueno; Tamer M Fouad; Kenichi Harano; Bisrat G Debeb; Yun Wu; James Reuben; Massimo Cristofanilli; Zhuang Zuo
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

3.  Involvement of epigenetics and EMT-related miRNA in arsenic-induced neoplastic transformation and their potential clinical use.

Authors:  Christina Michailidi; Masamichi Hayashi; Sayantan Datta; Tanusree Sen; Kaitlyn Zenner; Oluwadamilola Oladeru; Mariana Brait; Evgeny Izumchenko; Alexander Baras; Christopher VandenBussche; Maria Argos; Trinity J Bivalacqua; Habibul Ahsan; Noah M Hahn; George J Netto; David Sidransky; Mohammad Obaidul Hoque
Journal:  Cancer Prev Res (Phila)       Date:  2015-01-13

4.  MicroRNAs and cancer: Key paradigms in molecular therapy.

Authors:  Weige Tan; Bodu Liu; Shaohua Qu; Gehao Liang; Wei Luo; Chang Gong
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

5.  Identification of miR-146a is Associated with the Aggressiveness and Suppresses Proliferation via Targeting CDKN2A in Breast Cancer.

Authors:  Yanping Zhang; Shi Ding; Jie Yang; Xingfeng Chen; Weilin Huang
Journal:  Pathol Oncol Res       Date:  2018-06-18       Impact factor: 3.201

6.  MicroRNA-205 directly regulates the tumor suppressor, interleukin-24, in human KB oral cancer cells.

Authors:  Jae-Sung Kim; Sun-Kyoung Yu; Myoung-Hwa Lee; Min-Gyeong Park; Euteum Park; Su-Gwan Kim; Sook-Young Lee; Chun Sung Kim; Heung-Joong Kim; Hong Sung Chun; Sang-Woo Chun; Do Kyung Kim
Journal:  Mol Cells       Date:  2012-12-03       Impact factor: 5.034

7.  MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.

Authors:  Hyun Jin Cho; Guoxiang Liu; Seok Min Jin; Loukia Parisiadou; Chengsong Xie; Jia Yu; Lixin Sun; Bo Ma; Jinhui Ding; Renée Vancraenenbroeck; Evy Lobbestael; Veerle Baekelandt; Jean-Marc Taymans; Ping He; Juan C Troncoso; Yong Shen; Huaibin Cai
Journal:  Hum Mol Genet       Date:  2012-11-02       Impact factor: 6.150

Review 8.  Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: Quo vadis?

Authors:  Gerasimos Socrates Christodoulatos; Maria Dalamaga
Journal:  World J Clin Oncol       Date:  2014-05-10

9.  Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer.

Authors:  Claudia Piovan; Dario Palmieri; Gianpiero Di Leva; Luca Braccioli; Patrizia Casalini; Gerard Nuovo; Monica Tortoreto; Marianna Sasso; Ilaria Plantamura; Tiziana Triulzi; Cristian Taccioli; Elda Tagliabue; Marilena V Iorio; Carlo M Croce
Journal:  Mol Oncol       Date:  2012-04-19       Impact factor: 6.603

10.  Genomic analysis of microRNA time-course expression in liver of mice treated with genotoxic carcinogen N-ethyl-N-nitrosourea.

Authors:  Zhiguang Li; William S Branham; Stacey L Dial; Yexun Wang; Lei Guo; Leming Shi; Tao Chen
Journal:  BMC Genomics       Date:  2010-10-28       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.